Unigene States that New Government Study Reports Many Osteoporosis Medications Prevent Fractures, but None is Proven Best
23 April 2008 15:24
Unigene Laboratories reports that a comparative analysis of various osteoporosis therapies has been published, concluding that there is insufficient evidence to support claims of superior effectiveness among the drugs reviewed.
The study, commissioned by the Agency for Healthcare Research and Quality, Department of Health and Human Services, is entitled The Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. The study was performed by the Southern California/RAND Evidence-based Practice Center to assist physicians, patients, private- and public-sector organizations in making informed decisions about pharmaceutical alternatives for osteoporosis and reviewed data for bisphosphonates, calcitonin, parathyroid hormone, estrogen, selective estrogen receptor modulators and testosterone.
The leading category of osteoporosis drugs is the bisphosphonates, with established efficacy in reducing fractures in osteoporosis patients. However, according to the report, not enough scientific evidence exists to establish whether bisphosphonates are better at preventing fractures than calcitonin, estrogen or raloxifene. Additionally, certain bisphosphonates have been associated with osteonecrosis. Separately, the FDA is currently conducting a safety review of all bisphosphonate products and their possible link to atrial fibrillation, an established risk factor for stroke.
Findings in the report cite evidence that calcitonin has also demonstrated a reduction in fracture risk among post-menopausal women as well as men. The global history of calcitonin products demonstrates an impressive safety profile, with products being administered to patients for more than 35 years with virtually no significant side effects.
Calcitonin is the active ingredient in Fortical®, a nasal calcitonin product developed by Unigene and marketed by Upsher-Smith Laboratories.
"The study suggests that many of the available products are effective in treating osteoporosis sufferers, yet there is little evidence to support differentiation of the products based on effectiveness," commented Dr. Warren Levy, President and CEO of Unigene. "The study also indicates that adherence to the therapy is an important factor in patient outcome. We hope that this study will encourage physicians and patients to recognize that, if there are acceptable alternatives for patients with osteoporosis or low bone density, and long-term therapy is desirable, then the side effect/safety profile of each drug should be considered carefully before treatment decisions are made."
For more information on this company:
Unigene - Oral and Nasal Delivered Peptide Drugs
Copyright 2008 SPG Media Limited a subsidiary of SPG Media Group PLC
